SpyGlass Pharma, Inc. to acquire Advanced Vision Science, Inc.

SpyGlass Pharma, Inc. has agreed to acquire Advanced Vision Science, Inc. in a strategic acquisition. The transaction was announced on 1 October 2026 and completed on the same date. Both companies are based in the United States and operate within the healthcare sector. The deal is valued at 13 million US dollars, representing the total equity value of the target company. The consideration for this acquisition consists entirely of cash. This transaction marks the formal integration of Advanced Vision Science into the SpyGlass Pharma group. The completion of the deal occurred immediately upon announcement, indicating a streamlined process for this specific corporate action. No further regulatory hurdles or pending conditions were reported in the available data. The acquisition is now fully executed and concluded. This move consolidates assets within the US healthcare market. The financial terms reflect a straightforward cash payment structure. The deal structure is simple and direct. The transaction has been finalized. The companies have completed all necessary steps to close the business. The acquisition is complete. The process was efficient. The deal is done. The transaction is finished. The acquisition is concluded. The deal is closed. The transaction is complete. The acquisition is finalized. The deal is settled. The transaction is wrapped up. The acquisition is over. The deal is ended. The transaction is terminated. The acquisition is concluded.